Well I can tell you this for a fact, once the FDA approves Sofdra in June, Bot is going to hit the ground running;
The Company has been ramping up commercial launch preparation activities in recent weeks following
filing of the resubmission of the Sofdra NDA and has focused on engaging US payers (insurers) around
contracting and pricing for the product, as well as preparing patient and physician-focused launch
marketing and sales materials, testing telemedicine and supply chain elements, and finalising sales
strategies.
Ann: NDA Resubmission Accepted and Approval Date Confirmed, page-24
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
27.8¢ |
Change
-0.008(2.63%) |
Mkt cap ! $448.9M | |||
| Open | High | Low | Value | Volume |
| 28.5¢ | 30.8¢ | 27.8¢ | $2.630M | 8.955M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 11 | 1007927 | 27.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 28.0¢ | 260483 | 13 |
View Market Depth
| Last trade - 15.51pm 21/05/2024 (20 minute delay) ? |
|
|||||
|
Last
28.3¢ |
Change
-0.008 ( 2.72 %) |
||||
| Open | High | Low | Volume | ||
| 29.0¢ | 30.5¢ | 27.8¢ | 3452172 | ||
| Last updated 15.59pm 21/05/2024 ? | |||||
| BOT (ASX) Chart |